SCOLR Pharma, a provider of derug delivery technology products, has reported revenues of $1.24m for the third quarter ended 30 September 2010, a decrease of 53%, compared to $2.62m for the same period in 2009.
SCOLR Pharma has posted a net loss of $ $8.7m for the third quarter 30 September 2010, or $0.02 per diluted share, compared to net loss of $1.6m, or $0.04 per diluted share, for the comparable period in 2009.
SCOLR Pharma has reported an operating income of $8.69m, compared to $1. 58 for the same period in 2009.
For the nine months ended 30 September 2010, the company has posted total revenues of $5.13m, compared to $6.64 for the year ago period.
SCOLR Pharma has posted a net loss of $2.40m, or $0.05 per diluted share, compared to $5.06m, or $0.12 per diluted share, for the year ago period and operating loss was $2.39m, compared to $5.07 for the year ago period.
SCOLR Pharma president and CEO Stephen Turner said that their focus for the remainder of the year will be to continue executing the plans for their extended release nutritional supplement and drug delivery businesses, which have both been advanced in the last quarter.